《泰閣於臨床重症的應用》.pptVIP

泰閣於臨床重症的應用;各種抗生素之抗菌族譜;Tigecycline Dosing;泰閣之抗菌特點;;Tigecycline In Vitro Activity against 6,792 G(-) and G(+) Clinical Isolates-Global ;G(-) in Vitro Data – Taiwan;泰閣在組織內的分布(組織濃度/血清濃度);由抗菌族譜與藥物動力學衍生出之泰閣經驗性療法臨床適應症;含MRSA之複雜性皮膚軟組織感染(CSSTI);Predominant Isolates in Abscesses at Various Body Sites;Relative Distribution of Bacteria From Superficial to Deep Infections;FDA Classification of SSTIs;A Major Surgical Site Infection is a Catastrophe!;以糖尿病足為例來探討CSSTI之微生物學;Microbes and Chronic Wounds;Definitions;Microbiology of Wounds;Microbiology of Wounds;Microbiology of Wounds;Occurrence and Antimicrobial Susceptibility of Pathogens Isolated From SSTIs; MSSA (n=18)* MRSA (n=12)* Characteristics Age 57.4 (41–72) years 56.8 (40–75) years Duration of DM 10.4 (6.4–17.1) years 11.2 (7.1–18) years Neuropathic ulcers 50.0% 58.3% Ulcer area 2.74 (0.25–7.2) cm2 2.64 (0.16–10.5) cm2 Number of organisms 0.8 (0–2) 1.1 (0–3) HbA1c 9.0% ? 0.5% 8.9% ? 0.7% Creatinine 165.4 ? 42.1 mmol/L 148.8 ? 13.8 mmol/L Course Time to healing 17.8 (8–24) weeks 35.4 (19–64) weeks? Amputations 2 2 ;MRSA Surgical Site Infection Consequences;*Of the 724 patients with S. aureus bacteremia, 228 patients had a complicated infection at the time of the initial  hospitalization (some patients had more than 1 site of complicated infection). Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003;163:2066-2072.;*Breakpoint between early and delayed treatment was 44.75 hours. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003;36:1418-1423.;Vancomycin MIC creep over 5 years, NC, USA;Impact of Increasing Vancomycin Dosage;Tigecycline Phase III Clinical Studies;Clinical Cure* Rates in the CE Population in cSSSI Studies ;Cure Rates by Mono/Polymicrobial Infection in the ME Population in cSSSI Stu